MSKCC relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSKCC has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in many areas, including the Developmental and Stem Cell Biology Program, the Molecular Structure Program, the Prevention, Control and Population Research Program (now the Survivorship, Outcomes, and Risk Program), along with its efforts in Immigrant Health and Cancer Disparities, the Immunology and Transplantation Program, the Imaging and Radiation Sciences Program, the Cancer Biology and Experimental Pathology Program, Experimental Therapeutics, and disease-specific components of the Clinical Research Program. The BSC has also reviewed some of the newly recruited junior investigators and the training programs that bring outstanding students to train in MSKCC's laboratories. In addition to the BSC, the senior leaders receive strategic counsel from the MSKCC Board of Overseers and Managers to provide both community and financial stewardship as well as tactical advice on Center policies. A Task Force was also created to internally evaluate the Cores' infrastructure, and several improvements have been enacted. Through input from program members and the Associate Directors, further collaborative research centers that foster interactions between laboratory and clinical investigators have also been established. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.
MSKCC's planning and evaluation processes provide external and internal counsel for its research programs. The expert advice that it receives guides the development of its strategic initiatives so that it can best meet the mission of an NCI-designated Comprehensive Cancer Center.
|Pak, Linda M; Gonen, Mithat; Seier, Kenneth et al. (2018) Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol (NY) 43:2113-2118|
|Thomas, Rozario; Marks, Daniel Henry; Chin, Yvette et al. (2018) Whole chromosome loss and associated breakage-fusion-bridge cycles transform mouse tetraploid cells. EMBO J 37:201-218|
|Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386|
|Abreu, Carla M; Prakash, Rohit; Romanienko, Peter J et al. (2018) Shu complex SWS1-SWSAP1 promotes early steps in mouse meiotic recombination. Nat Commun 9:3961|
|Katsoulakis, Evangelia; Leeman, Jonathan E; Lok, Benjamin H et al. (2018) Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. Laryngoscope 128:2539-2545|
|Huicochea Castellanos, Sandra; Corrias, Giuseppe; Ulaner, Gary A et al. (2018) Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdom Radiol (NY) :|
|Hoseini, Sayed Shahabuddin; Guo, Hongfen; Wu, Zhihao et al. (2018) A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv 2:1250-1258|
|Attiyeh, Marc A; Fernández-Del Castillo, Carlos; Al Efishat, Mohammad et al. (2018) Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. Ann Surg 267:157-163|
|Tollinche, Luis; Tan, KaySee; Han, Austin et al. (2018) Analyzing Volatile Anesthetic Consumption by Auditing Fresh Gas Flow: An Observational Study at an Academic Hospital. Int J Anesth Anesth 5:|
|Tadros, Audree B; Wen, Hannah Y; Morrow, Monica (2018) Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Ann Surg Oncol 25:3158-3164|
Showing the most recent 10 out of 8799 publications